EXEL:NASDAQ
Exelixis Inc
$59.02
arrow_upward
+0.99%(+0.58) 1D
$59.02
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 8, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$58.07
High
$60.08
Low
$57.91
Mkt. cap
14.62B
Avg. vol.
2.13M
Volume
2.68M
P/E ratio
18.54
52-wk high
$61.14
52-wk low
$33.76
EPS
$3.18
Beta
0.47
Shares outstanding
247.78M
No. of employees
1K
Open
$58.07
High
$60.08
Low
$57.91
Mkt. cap
14.62B
Avg. vol.
2.13M
Volume
2.68M
P/E ratio
18.54
52-wk high
$61.14
52-wk low
$33.76
EPS
$3.18
Beta
0.47
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
Truist raises target for Exelixis stock to USD 54.00
Zacks
·
8 hours ago
Here's Why Exelixis (EXEL) is a Strong Value Stock
AD HOC NEWS
·
18 hours ago
Exelixis stock gets a higher Truist target at USD 54
Yahoo Finance
·
21 hours ago
Exelixis, Inc. (EXEL) Stock Forecasts
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com